7BIO

Aurora kinase B inhibitor



ALX-430-149-M005	5 mg	83.00 USD

ALX-430-149-M025	25 mg	330.00 USD

Induces a rapid caspase-independent cell death process distinct from apoptosis. Demonstrated selective inhibition of aurora kinase B (IC₅₀=4.6µM) and aurora kinase C (IC₅₀=0.7µM) whereas the homologeous aurora kinase A is poorly inhibited. Triggers inflammmasome activation and subsequent release of the pro-inflammatory cytokines of IL-1β and IL-18.

Product Specification

Alternative Name:	(2’Z, 3’E)-7-Bromoindirubin-3’-monoxime, MLS2156

Formula:	C₁₆H₁₀BrN₃O₂

MW:	356.2

Purity:	≥95% (¹H-NMR)

Appearance:	Dark brown solid.

CAS:	916440-85-2

Solubility:	Soluble in DMSO.

Long Term Storage:	-20°C

Hazard:	IRRITANT.

Handling:	Protect from light.

Please mouse over

Product Literature References

Anticancer effects and antimetastatic mechanisms of novel indirubin derivatives: C.A. Kressirer; PhD Thesis (2010), Full Text

Cutting edge: Necrosis activates the NLRP3 inflammasome: H. Li, et al.; J. Immunol. 183, 1528 (2009), Abstract;

7-Bromoindirubin-3’-oxime uncovers a serine protease-mediated paradigm of necrotic cell death: J. Ribas, et al.; Biochem. Pharmacol. 76, 39 (2008), Abstract;

An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins: V. Myrianthopoulos, et al.; J. Med. Chem. 50, 4027 (2007), Abstract;

3’-Substituted 7-halogenoindirubins, a new class of cell death inducing agents: Y. Ferandin, et al.; J. Med. Chem. 49, 4638 (2006), Abstract;

7-Bromoindirubin-3’-oxime induces caspase-independent cell death: J. Ribas, et al.; Oncogene 25, 6304 (2006), Abstract;